Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or
colorectal carcinoma (CRC) will receive a loading dose of cetuximab alone, followed 7 days
later by the first combination treatment of cetuximab and NKTR-255 on Cycle 1 Day 1 (C1D1).
Thereafter, intravenous (IV) NKTR-255 will be given in 21-day cycles in combination with
weekly IV cetuximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255
in combination with cetuximab, this dose of NKTR-255 will be further studied in patients with
HNSCC (Cohort A) and CRC (Cohort B) in Phase 2 of the study.